Sponsor Dossier
Petrus Pharmaceuticals
Sponsor Dossier for Petrus Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: BISACODYL
- Brand: Cal-500
- Brand: Cal-600
- Brand: Cal-600+D
- Brand: Centa-Vite
- Brand: Cranberry
- Brand: Hartley's Gripe Water Oral
- Brand: LITTLE
- Device (sponsor): Lubricant, eye
- Device (sponsor): Lubricant, eye
- Device (sponsor): Lubricant, eye
- Device (sponsor): General-body orifice lubricant, non-sterile
- Device (sponsor): Artificial saliva
- Device (sponsor): General-body orifice lubricant, sterile
- Device (sponsor): Medicine chamber spacer
- Device (sponsor): Lubricant, eye
About
Petrus Pharmaceuticals is an Australian Private Company with ABN 21 108 884 126, registered in Western Australia and currently active. The company has traded under the business names Myadec, Petrus Pharmaceuticals, and Unisom.
Portfolio
Petrus Pharmaceuticals has 21 brands on the ARTG, of which 6 are indexable and 0 carry a Product Information document. 6 brands are PBS-listed, 0 have a PBAC outcome on record, and 0 have an AusPAR on record. Notable brands include BISACODYL, Cal-500, Cal-600, Cal-600+D, Centa-Vite, Cranberry, Hartley's Gripe Water Oral, LITTLE, Macu-Gen, Mag-Sup, Myadec, ORAL-EZE.
Therapeutic focus
— Complementary Medicine: 13 brands — Gastroenterology: 4 brands — Musculoskeletal: 2 brands — Ophthalmology: 1 brand — Pain Management: 1 brand
PBS footprint
6 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2022-07-01, across 0 brands with a PBAC outcome on record.